MaxCyte, Inc. (NASDAQ:MXCT) Director Stanley C. Erck Sells 21,607 Shares of Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the sale, the director now owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

MaxCyte Stock Performance

MXCT opened at $3.74 on Thursday. The stock has a fifty day moving average of $4.16 and a 200-day moving average of $4.26. The company has a market capitalization of $392.04 million, a P/E ratio of -10.69 and a beta of 1.40. MaxCyte, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. The firm had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. On average, equities research analysts predict that MaxCyte, Inc. will post -0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MaxCyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company lifted its holdings in shares of MaxCyte by 25.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 42,289 shares of the company’s stock worth $166,000 after acquiring an additional 8,454 shares during the period. Marshall Wace LLP acquired a new stake in shares of MaxCyte in the 2nd quarter valued at $1,959,000. Renaissance Technologies LLC increased its stake in shares of MaxCyte by 29.7% in the 2nd quarter. Renaissance Technologies LLC now owns 210,914 shares of the company’s stock valued at $827,000 after purchasing an additional 48,314 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of MaxCyte by 13.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after buying an additional 121,090 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of MaxCyte by 10.7% during the 2nd quarter. American Century Companies Inc. now owns 144,110 shares of the company’s stock worth $565,000 after buying an additional 13,904 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.